Business Standard

Russia to supply 17 more countries with coronavirus drug Avifavir

Avifavir gained approval from the Russian health ministry in May and is based on favipiravir, which was developed in Japan and is widely used there as the basis for viral treatments

coronavirus drug, pharma

Clinical trials in Japan and Russia have confirmed those drugs' efficacy, the Russian Direct Investment Fund (RDIF) said in a statement.

Reuters MOSCOW
MOSCOW (Reuters) - Russia's sovereign wealth fund and its partner Chemrar will supply the COVID-19 drug Avifavir to 17 additional countries, the fund said in a statement on Thursday.
Avifavir gained approval from the Russian health ministry in May and is based on favipiravir, which was developed in Japan and is widely used there as the basis for viral treatments.
Clinical trials in Japan and Russia have confirmed those drugs' efficacy, the Russian Direct Investment Fund (RDIF) said in a statement.
 
(Reporting by Andrew Osborn; Writing by Alexander Marrow; Editing by Mark Trevelyan)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 24 2020 | 2:47 PM IST

Explore News